Phathom Moves To Defend Voquesna's Exclusivity Through May 2032 After Generic Maker Sues FDA
CEO Steve Basta says Phathom has intervened in BDR Pharmaceuticals' suit and will defend its position "vigorously."
Phathom Pharmaceuticals, which sells the acid-blocking drug Voquesna, has intervened in a lawsuit a generic drugmaker filed against the FDA over the drug's extended exclusivity, CEO Steve Basta said on the company's third-quarter earnings call Thursday. Basta said Phathom intends to vigorously defend its position.
A suit aimed at Voquesna's protection
Basta said BDR Pharmaceuticals sued the FDA on October 21, 2026. The suit principally challenges what he described as the agency's alleged refusal to receive BDR's generic application referencing Phathom's new drug application, and it alleges the FDA improperly applied the GAIN Act to extend new-chemical-entity exclusivity for Voquesna tablets.
A second purported generic applicant has since filed a notice that it intends to move to consolidate its case with BDR's, Basta said.
The FDA reached its position in June 2025 after reviewing Phathom's citizen petition, he said: 10 years of exclusivity, as extended by the GAIN Act, applies to all products containing vonoprazan. That put Voquesna tablets' exclusivity through May 3, 2032, and the FDA updated the Orange Book, its drug-approval listing, to match.
On October 23, 2026, the FDA opened a public docket for 30 days to collect comment on legal and regulatory questions raised by BDR's suit, which the agency considers new compared with the citizen petition, Basta said. "We believe the FDA arrived at the correct decision," he said.
No forecast on next steps
An analyst from Cantor Fitzgerald asked what Phathom expects next. Basta said litigation is "an inherently fluid process" and that the company would not predict each step, calling such cases commonplace in the industry.
The business behind the fight
Phathom is a commercial-stage biopharmaceutical company whose vonoprazan-based products treat gastrointestinal diseases, including reflux disease. Third-quarter net revenue was $84.7 million, up about 71% from a year earlier and about 14% from the second quarter. The company reiterated full-year revenue guidance of $310 million to $325 million.
Over 2 million Voquesna prescriptions had been filled from launch through October 16, Basta said. Phathom ended the quarter with $184.6 million in cash and cash equivalents.
Basta said Phathom aims to bring in more GI products it could launch before exclusivity is lost in 2033, so the company expects to strike one or more deals in coming years.
The FDA's 30-day docket, opened October 23, is the next dated step, along with whether the second applicant's bid to consolidate its case with BDR's goes forward.
Sources
- Phathom Pharmaceuticals Non-GAAP EPS of $0.04 beats by $0.01, revenue of $84.7M misses by $0.12M (PHAT:NASDAQ) | Seeking Alpha — seekingalpha.com
- Phathom Pharmaceuticals Q3 2026 Earnings Preview | Seeking Alpha — seekingalpha.com
- Phathom Pharmaceuticals Provides Update on FDA Litigation — Yahoo Finance
- Phathom Pharmaceuticals Reports Third Quarter 2026 — rss.globenewswire.com